6919 — Caliway Biopharmaceuticals Co Share Price
0.000.00%
Last trade - 00:00- TWD94.62bn
- TWD84.96bn
- TWD44.43m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 54.54 | ||
| PEG Ratio (f) | 0.57 | ||
| EPS Growth (f) | 2,487.94% | ||
| Dividend Yield (f) | 1.73% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.76 | ||
| Price to Tang. Book | 9.76 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,129.46 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.38% | ||
| Return on Equity | -8.76% | ||
| Operating Margin | -1613.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 10.35 | 12.34 | 12.82 | 38.93 | 44.43 | 3,041 | 5,910 | 18.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +31.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Caliway Biopharmaceuticals Co Ltd is a Taiwan-based company mainly engaged in the sale of health food, the development of drugs and technical consulting. The drugs developed by the Company are all small molecule drugs, including CBL-514, CBA-539, CBO-012 and CBF-520. CBL-514 is used for non-surgical local fat reduction, cellulite, Baergen's disease and lipoma and others. It is in the second clinical stage. CBA-539 is used for pigmentation, whitening and anti-aging, and it is in the non-clinical research stage. CBO-012 is in the non-clinical research stage for degenerative arthritis. CBF-520 is used for central obesity and non-alcoholic fatty liver disease, and it is in the non-clinical research stage. The Company's sales revenue comes from health food, which is sold by agents and distributors, with Taiwan and China as the main sales areas.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 22nd, 2012
- Public Since
- December 26th, 2022
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 154,608,786
- Address
- 32F-9, No.99, Section 1,, NEW TAIPEI, 221
- Web
- https://www.caliway.com.tw/
- Phone
- +886 null226971355
- Contact
- Yufang Ling
- Auditors
- KPMG LLP
Upcoming Events for 6919
Caliway Biopharmaceuticals Co Ltd Annual Shareholders Meeting
Similar to 6919
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
BRIM Biotechnology
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech Co
Taiwan Stock Exchange
FAQ
What is the Caliway Biopharmaceuticals Co share price?
As of Today at 19:44 UTC, shares in Caliway Biopharmaceuticals Co are trading at TWD612.00. This share price information is delayed by 15 minutes.
How has the Caliway Biopharmaceuticals Co share price performed this year?
Shares in Caliway Biopharmaceuticals Co last closed at TWD612.00 and the price had moved by +56.52% over the past 365 days. In terms of relative price strength the Caliway Biopharmaceuticals Co share price has outperformed the FTSE Developed Asia Pacific Index by +58.31% over the past year.
What are the analyst and broker recommendations for Caliway Biopharmaceuticals Co?
The overall consensus recommendation for Caliway Biopharmaceuticals Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Caliway Biopharmaceuticals Co dividend yield?
Caliway Biopharmaceuticals Co does not currently pay a dividend.
Does Caliway Biopharmaceuticals Co pay a dividend?
Caliway Biopharmaceuticals Co does not currently pay a dividend.
When does Caliway Biopharmaceuticals Co next pay dividends?
Caliway Biopharmaceuticals Co does not currently pay a dividend.
How do I buy Caliway Biopharmaceuticals Co shares?
To buy shares in Caliway Biopharmaceuticals Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Caliway Biopharmaceuticals Co?
As of the previous close price of TWD612.00, shares in Caliway Biopharmaceuticals Co had a market capitalisation of TWD94.62bn.
Where are Caliway Biopharmaceuticals Co shares listed?
Here are the trading details for Caliway Biopharmaceuticals Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6919
What kind of share is Caliway Biopharmaceuticals Co?
Based on an overall assessment of its quality, value and momentum Caliway Biopharmaceuticals Co is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Caliway Biopharmaceuticals Co share price forecast for 2025?
The analyst consensus target price for shares in Caliway Biopharmaceuticals Co is TWD1,040.00. That is 69.93% above the last closing price of TWD612.00.
Analysts covering Caliway Biopharmaceuticals Co currently have a consensus Earnings Per Share (EPS) forecast of TWD10.21 for the next financial year.
Find out moreWhat is the trend in the Caliway Biopharmaceuticals Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Caliway Biopharmaceuticals Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +31.01%.
As of the last closing price of TWD612.00, shares in Caliway Biopharmaceuticals Co were trading -6.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Caliway Biopharmaceuticals Co PE Ratio?
The Caliway Biopharmaceuticals Co PE ratio based on its reported earnings over the past 12 months is 54.54. The shares last closed at TWD612.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Caliway Biopharmaceuticals Co?
We do not have data on Caliway Biopharmaceuticals Co's directors